WO2006024367A3 - Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen - Google Patents

Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen Download PDF

Info

Publication number
WO2006024367A3
WO2006024367A3 PCT/EP2005/008579 EP2005008579W WO2006024367A3 WO 2006024367 A3 WO2006024367 A3 WO 2006024367A3 EP 2005008579 W EP2005008579 W EP 2005008579W WO 2006024367 A3 WO2006024367 A3 WO 2006024367A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble
nkg2d
blockers
ligand interaction
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/008579
Other languages
English (en)
French (fr)
Other versions
WO2006024367A2 (de
Inventor
Alexander Steinle
Manuel Friese
Heinz Wiendl
Michael Weller
Bettina Schreiner
Robert Weissert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Priority to EP05773900A priority Critical patent/EP1848452A2/de
Publication of WO2006024367A2 publication Critical patent/WO2006024367A2/de
Publication of WO2006024367A3 publication Critical patent/WO2006024367A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten, insbesondere der Multiplen Sklerose, sowie zur Blockierung des NKG2D-Rezeptors, wobei die Blocker ausgewählt sind aus der Gruppe umfassend löslicher NKG2D-Rezeptor, lösliches MICA, lösliches MICE, lösliches ULBP1, lösliches ULBP2, lösliches ULBP3, lösliches ULBP4, lösliches RAET1L, lösliches RAET1G, sowie allelische Varianten oder Fragmente oder Derivate der genannten Blocker, sowie synthetisch hergestellte Blocker der NKG2D-Rezeptor/NKG2D-Liganden-Interaktion.
PCT/EP2005/008579 2004-08-30 2005-08-08 Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen Ceased WO2006024367A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05773900A EP1848452A2 (de) 2004-08-30 2005-08-08 Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004042894.8 2004-08-30
DE102004042894A DE102004042894A1 (de) 2004-08-30 2004-08-30 Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
WO2006024367A2 WO2006024367A2 (de) 2006-03-09
WO2006024367A3 true WO2006024367A3 (de) 2006-06-15

Family

ID=35462321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008579 Ceased WO2006024367A2 (de) 2004-08-30 2005-08-08 Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen

Country Status (3)

Country Link
EP (1) EP1848452A2 (de)
DE (1) DE102004042894A1 (de)
WO (1) WO2006024367A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2012091756A1 (en) * 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
CA2823297C (en) * 2010-12-30 2021-05-25 Avidbiotics Corp. Non-natural mic proteins
EP2970490A4 (de) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antikörper gegen mica- und micb-proteine
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
CA3040421A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
CN112500497B (zh) * 2020-12-14 2021-06-08 南京凯地医疗技术有限公司 Cltx-nkg2d双特异性嵌合抗原受体细胞及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029436A2 (en) * 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029436A2 (en) * 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACKSTROM E ET AL: "Activation of natural killer cells: Underlying molecular mechanisms revealed", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 60, no. 1-2, 1 August 2004 (2004-08-01), pages 14 - 22, XP002360676, ISSN: 0300-9475 *
OGASAWARA KOUETSU ET AL: "NKG2D blockade prevents autoimmune diabetes in NOD mice", IMMUNITY, vol. 20, no. 6, June 2004 (2004-06-01), pages 757 - 767, XP002360662, ISSN: 1074-7613 *
STEINLE ALEXANDER ET AL: "Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family", IMMUNOGENETICS, vol. 53, no. 4, May 2001 (2001-05-01), pages 279 - 287, XP002360705, ISSN: 0093-7711 *
WIEMANN K ET AL: "Danger-detector NKG2D: Immunosurveillance of induced self and modulation by cytokines and soluble ligands", CURRENT MEDICINAL CHEMISTRY - ANTI-INFLAMMATORY & ANTI-ALLERGY AGENTS, vol. 4, no. 2, April 2005 (2005-04-01), pages 141 - 152, XP008057752, ISSN: 1568-0142 *

Also Published As

Publication number Publication date
WO2006024367A2 (de) 2006-03-09
DE102004042894A1 (de) 2006-03-02
EP1848452A2 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
NZ615012A (en) Combinatorial therapy involving alpha5beta1 antagonists
WO2007147090A3 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
EP1135477A4 (de) Humanisierte monoklonale antikörper
JP2018029595A5 (de)
WO2006013472A3 (en) Novel anti-igf-ir antibodies and uses thereof
WO2004009015A3 (en) Combination therapy for the treatment of obesity
UA95304C2 (ru) Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов
WO2003013537A3 (en) Irinotecan for treatment of cancer
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005058967A8 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2004007553A8 (en) Antibodies anti-c5 component of the complement system and their use
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
WO2002065985A3 (en) Methods of treating diabetes mellitus
WO2006024367A3 (de) Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen
NZ574978A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
WO2008074329A3 (en) Modulation of activity of proneurotrophins
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
MXPA04004745A (es) Agonista de receptor de dopamina-d2 parcial y actividad inhibidora de serotonina y/o noradrenalina.
JP2009519025A5 (de)
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2005097778A8 (en) Tetrahydrobenzazepines as histamine h3 receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2005773900

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005773900

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005773900

Country of ref document: EP